Skip to content
DataLookout
Menu

NCT02625961

Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

StatusTerminated
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 102 versions: 46 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 13, 2026 Show 6 more changesShow less
    • Eligibility criteria expanded, about 24 words
    • Primary endpoints revised (4)
    • Interventions: Favezelimab/pembrolizumab coformulation (Biological), Pembrolizumab (Biological), Pembrolizumab/vibostolimab coformulation (Biological) to Favezelimab/pembrolizumab coformulation (Biological), Pembrolizumab (Biological), Pembrolizumab/vibostolimab coformulation (Biological)
    • Secondary endpoints: 8 to 49
    • Publications: details revised at 2 of 2 entries
    • Study arms: 2 to 4
  2. Notable Trial status: Completed to Terminated
    • Sponsor's reason: Business Reasons
    v101
  3. Minor Trial status: Active, Not Recruiting to Completed
    • Enrollment target: estimated 320 to confirmed 296
    • Primary and study completion dates changed from estimate of Nov 15, 2025 to Nov 5, 2025
    v100
  4. Minor Primary and study completion dates: Oct 31, 2025 to Nov 15, 2025v99
  5. Minor Primary and study completion dates moved earlier to Oct 31, 2025v98
Show 41 earlier versionsHide 41 earlier versions
  1. Notable Primary endpoints: 5 to 4
    • Secondary endpoints: 11 to 8
    • Study description expanded, about 19 words
    v96
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 25 to 0
    v95
  3. Minor Study sites: 26 to 25v94
  4. Minor Study sites: 25 to 26v92
  5. Minor Study sites: 24 to 25v91
  6. Minor Study sites: 23 to 24v90
  7. Minor Study sites: 24 to 23v89
  8. Minor Study sites: 22 to 24v88
  9. Notable Primary endpoints: 3 to 5
    • Secondary endpoints: 1 to 11
    v87
  10. Minor Study sites: 21 to 22v86
  11. Minor Study sites: 20 to 21v85
  12. Minor Site details revised at 1 of 20 sitesv84
  13. Minor Site details revised at 1 of 20 sitesv83
  14. Minor Study sites: 19 to 20v82
  15. Minor Site details revised at 1 of 19 sitesv81
  16. Minor Site details revised at 1 of 19 sitesv80
  17. Minor Study sites: 18 to 19v79
  18. Notable Eligibility criteria revisedv78
  19. Minor Study sites: 17 to 18v76
  20. Minor Study sites: 15 to 17v75
  21. Minor Study sites: 14 to 15v74
  22. Minor Study sites: 13 to 14v73
  23. Notable Eligibility criteria revisedv72
  24. Minor Study sites revised (13)v71
  25. Minor Site details revised at 1 of 13 sitesv70
  26. Minor Study sites revised (13)v69
  27. Notable Trial status: Active, Not Recruiting to Recruiting
    • Study sites: 0 to 13
    v68
  28. Notable Primary completion date: Jul 26, 2022 to Aug 30, 2026v67 Show 7 more changesShow less
    • Primary endpoints: 2 to 3
    • Eligibility criteria expanded, about 4 words
    • Enrollment target: 260 to 320
    • Study completion date: Jul 30, 2023 to Aug 31, 2030
    • Interventions: pembrolizumab (Biological) to Favezelimab/pembrolizumab coformulation (Biological), Pembrolizumab (Biological), Pembrolizumab/vibostolimab coformulation (Biological)
    • Study title expanded, about 6 words
    • Study arms: 1 to 2
  29. Minor Primary completion date: Jun 15, 2022 to Jul 26, 2022v66
  30. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 27 to 0
    v65
  31. Minor Study sites: 29 to 27v64
  32. Minor Study sites: 30 to 29v63
  33. Minor Site details revised at 1 of 30 sitesv62
  34. Minor Site contacts updated at 1 of 30 sitesv60
  35. Minor Site contacts updated at 1 of 30 sitesv59
  36. Minor Site contacts updated at 1 of 30 sitesv58
  37. Minor Site details revised at 1 of 30 sitesv57
  38. Minor Study sites: 32 to 30v56
  39. Minor Study sites: 34 to 32v55
  40. Minor Study sites: 35 to 34v54
  41. Minor Study sites: 36 to 35v53
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Cohort A: Complete Response (CR) Rate of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)
Timeframe: Up to approximately 84 months
Cohort B: 12-month Disease-Free Survival (DFS) Rate of High-Risk NMIBC
Timeframe: Up to approximately 12 months
Cohort A and B: Number of Participants Who Experienced an Adverse Event (AE)
Timeframe: Up to approximately 113 months
Cohort A and B: Number of Participants Who Discontinued Study Treatment Due to an AE
Timeframe: Up to approximately 27 months

Secondary (49)

Cohort A: CR Rate of Any Disease
Cohort A: CR Rate of High-Risk NMIBC in Programmed Cell Death 1 (PDL-1) Combined Positive Score (CPS) <10 Participants
Cohort A: CR Rate of High-Risk NMIBC in PDL-1 CPS ≥10 Participants
Cohort A: CR Rate of Any Disease in PDL-1 CPS <10 Participants
Cohort A: CR Rate of Any Disease in PDL-1 CPS ≥10 Participants
Show 44 moreShow less
Cohort A: Duration of Response (DOR) of High-Risk NMIBC
Cohort A: DOR of Any Disease
Cohort A: DOR of High-Risk NMIBC in PDL-1 CPS <10 Participants
Cohort A: DOR of High-Risk NMIBC in PDL-1 CPS ≥10 Participants
Cohort A: DOR of Any Disease in PDL-1 CPS <10 Participants
Cohort A: DOR of Any Disease in PDL-1 CPS ≥10 Participants
Cohort A: DOR Rate of High-Risk NMIBC
Cohort A: DOR Rate of High-Risk NMIBC in PDL-1 CPS <10 Participants
Cohort A: DOR Rate of High-Risk NMIBC in PDL-1 CPS ≥10 Participants
Cohort A: DOR Rate of Any Disease
Cohort A: DOR Rate of Any Disease in PDL-1 CPS <10 Participants
Cohort A: DOR Rate of Any Disease in PDL-1 CPS ≥10 Participants
Cohort A and B: Progression-Free Survival (PFS) to Worsening of Grade or Stage to Death
Cohort A and B: PFS to Worsening of Grade or Stage to Death in PDL-1 CPS <10 Participants
Cohort A and B: PFS to Worsening of Grade or Stage to Death in PDL-1 CPS ≥10 Participants
Cohort A and B: PFS to Muscle-Invasive or Metastatic Disease or Death
Cohort A and B: PFS to Muscle-Invasive or Metastatic Disease or Death in PDL-1 CPS <10 Participants
Cohort A and B: PFS to Muscle-Invasive or Metastatic Disease or Death in PDL-1 CPS ≥10 Participants
Cohort A and B: Overall Survival (OS)
Cohort A and B: OS in PD-L1 CPS <10 Participants
Cohort A and B: OS in PD-L1 CPS ≥10 Participants
Cohort B: 12-month DFS Rate of Any Disease
Cohort B: 12-month DFS Rate of High-Risk NMIBC in PDL-1 CPS <10 Participants
Cohort B: 12-month DFS Rate of High-Risk NMIBC in PDL-1 CPS ≥10 Participants
Cohort B: 12-month DFS Rate of Any Disease in PDL-1 CPS <10 Participants
Cohort B: 12-month DFS Rate of Any Disease in PDL-1 CPS ≥10 Participants
Cohort B: Overall DFS of High-Risk NMIBC
Cohort B: Overall DFS of Any Disease
Cohort B: Overall DFS of High-Risk NMIBC in PDL-1 CPS <10 Participants
Cohort B: Overall DFS of High-Risk NMIBC in PDL-1 CPS ≥10 Participants
Cohort B: Overall DFS of Any Disease in PDL-1 CPS <10 Participants
Cohort B: Overall DFS of Any Disease in PDL-1 CPS ≥10 Participants
Cohort B: 3 Month DFS Rate of High-Risk NMIBC
Cohort B: 3 Month DFS Rate of Any Disease
Cohort B: 3 Month DFS Rate of High-Risk NMIBC in PDL-1 CPS <10 Participants
Cohort B: 3 Month DFS Rate of High-Risk NMIBC in PDL-1 CPS ≥10 Participants
Cohort B: 3 Month DFS Rate of Any Disease in PDL-1 CPS <10 Participants
Cohort B: 3 Month DFS Rate of Any Disease in PDL-1 CPS ≥10 Participants
Cohort B: 6 Month DFS Rate of High-Risk NMIBC
Cohort B: 6 Month DFS Rate of Any Disease
Cohort B: 6 Month DFS Rate of High-Risk NMIBC in PDL-1 CPS <10 Participants
Cohort B: 6 Month DFS Rate of High-Risk NMIBC in PDL-1 CPS ≥10 Participants
Cohort B: 6 Month DFS Rate of Any Disease in PDL-1 CPS <10 Participants
Cohort B: 6 Month DFS Rate of Any Disease in PDL-1 CPS ≥10 Participants

Arms and interventions

Cohort A: PembrolizumabExperimental

Participants with carcinoma-in-situ (CIS) with or without papillary tumors will receive pembrolizumab, 200 mg, intravenously, every 3 weeks (Q3W) for up to 24 months.

Cohort B: PembrolizumabExperimental

Participants with papillary tumors only, without CIS will receive pembrolizumab, 200 mg, intravenously, Q3W for up to 24 months.

Cohort C: Pembrolizumab/VibostolimabExperimental

Participants with CIS with or without papillary tumors will receive pembrolizumab/vibostolimab coformulation intravenously Q3W for up to 24 months.

Cohort C: Favezelimab/PembrolizumabExperimental

Participants with CIS with or without papillary tumors will receive favezelimab/pembrolizumab coformulation intravenously Q3W for up to 24 months.

Biologicals: Pembrolizumab, Pembrolizumab/vibostolimab coformulation, Favezelimab/pembrolizumab coformulation